Combination of post-operative radiotherapy and cetuximab for high-risk cutaneous squamous cell cancer of the head and neck: A propensity score analysis

Palmer, Joshua D.; Schneider, Charles J.; Hockstein, Neil; Hanlon, Alexandra L.; Silberg, Jordan; Strasser, Jon; Dzeda, Michael; Witt, Robert L.; Raben, Adam

doi:10.1016/j.oraloncology.2018.01.015

Cited by 23 publications

(19 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A retrospective study in patients with resected highrisk cSCC investigated RT combined with cetuximab (n Z 29) or RT alone (n Z 39). There were better progression-free survival rates for the combination therapy than with RT alone (2 years: 72% versus 53%, 5 years: 66% versus 29%, respectively) [69]. Currently, there is no robust evidence to support the use of adjuvant systemic treatment for cSCC, but clinical trials on the PD-1 antibodies cemiplimab and pembrolizumab are currently being conducted.…”

Section: Adjuvant Systemic Therapymentioning

confidence: 99%

European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment

Stratigos

Garbe²,

Dessinioti

et al. 2020

European Journal of Cancer

251

371

View full text Add to dashboard Cite

Section: Adjuvant Systemic Therapymentioning

confidence: 99%

European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment

Stratigos

Garbe²,

Dessinioti

et al. 2020

European Journal of Cancer

251

371

View full text Add to dashboard Cite

“…Regarding EGFR inhibitors, there are limited data in the curative and postoperative setting. Specifically, postoperative cetuximab concurrent with radiotherapy (n=29) versus radiation therapy alone (n=39) in patients with high-risk head and neck CSCC (high grade of differentiation, perineural or lymphovascular invasion, positive surgical margins, lymph node involvement, tumor recurrence, immunosuppression, localization to ear, cheek, lip), showed an advantage in terms of both freedom from local recurrence and freedom from distant recurrence (31). In the advanced setting, a phase II study including 36 patients with CSCC showed a response rate of 28% with a median duration of response of 6.8 months (32).…”

Section: The Old Therapeutic Optionsmentioning

confidence: 99%

Immunotherapy for the Treatment of Cutaneous Squamous Cell Carcinoma

et al. 2021

View full text Add to dashboard Cite

Cutaneous squamous cell carcinoma (CSCC) accounts for approximately 20% of all keratinocytic tumors. In most cases, the diagnosis and treatments are made on small, low-risk lesions. However, in about 5% of cases, CSCC may present as either locally advanced or metastatic (i.e. with locoregional lymph nodes metastases or distant localizations). Prior to the introduction of immunotherapy in clinical practice, the standard treatment of advanced CSCC was not clearly defined, and up to 60% of patients received no systemic therapy. Thanks to a strong pre-clinical rationale, clinical trials led to the FDA (Food and Drug Administration) and EMA (European Medicines Agency) registration of cemiplimab, a PD-1 inhibitor that achieved encouraging results in terms of objective response, overall survival, and quality of life. Subsequently, the anti-PD-1 pembrolizumab received the approval for the treatment of advanced CSCC by the FDA only. In this review, we will focus on the definition of advanced CSCC and on the current and future therapeutic options, with a particular regard for immunotherapy.

show abstract

“…Нет достоверных доказательств эффективности адъювантной системной терапии локализованного ПКРК после резекции R0 [128][129][130][131][132][133]. Адъювантная терапия 13-цисретиноевой кислотой и интерфероном не отдаляла возникновение рецидива или новой первичной опухоли [131].…”

Section: адъювантная системная терапияunclassified

Current strategy of squamous cell carcinoma diagnosis and treatment

Поляков

Gevorkov

Степанова

2021

Opuholi golovy i šei

View full text Add to dashboard Cite

Squamous cell carcinoma (SCC) is the second most common skin cancer after basal cell carcinoma. Usually, antitumor treatment is sufficiently effective: recovery rate is about 90 %. Primary SCC is characterized by variable growth rate, as well as by involvement of regional lymph nodes (from 1 % for well differentiated tumors to 10 % for poorly differentiated tumors, size >3 cm and /or invasion depth >4 mm). In case of SCC development near post-burn scar, the rate of regional metastasis is 10-30 %. A relatively small possibility of distant metastasis also exists, with overall mortality of 2-3 %. In SCC of the head and neck, both hematogenic and perineural advancement into the CNS are possible. Total rate of local recurrences is 25 %. The main factors of local and regional recurrences are location (head and neck), size (tumor diameter >2 cm), invasion depth (>4 mm), tumor differentiation, perineural involvement, patient's immune status and previous treatment. Tumors in areas that weren»t subjected to solar radiation and tumors in the areas of pervious irradiation, thermal damage, scarring or chronic ulcers are more prone to recurrences and metastasis. Poorly differentiated and anaplastic SCC is more likely to metastasize compared to well differentiated tumors. Medially located SCC is the area of the face mask and lip is more prone to neural invasion. Multidisciplinary approach with involvement of all specialists in antitumor treatment is necessary for development of treatment tactics.

show abstract

Combination of post-operative radiotherapy and cetuximab for high-risk cutaneous squamous cell cancer of the head and neck: A propensity score analysis

Cited by 23 publications

References 12 publications

European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment

European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment

Immunotherapy for the Treatment of Cutaneous Squamous Cell Carcinoma

Current strategy of squamous cell carcinoma diagnosis and treatment

Contact Info

Product

Resources

About